| CIMP subgroup (n, %) | P | ||||
---|---|---|---|---|---|---|
 | L | M | H | L vsM | M vsH | L vsH |
 | 19 (21) | 13 (14) | 59 (65) |  |  |  |
Female | 6 (32) | 4 (31) | 30 (51) | Â | Â | Â |
Male | 13 (68) | 9 (69) | 29 (49) | 0.952 | 0.211 | 0.175 |
Age ≥ 67 years | 6 (32) | 5 (38) | 37 (63) |  |  |  |
Age < 67 years | 13 (68) | 8 (62) | 22 (37) | 0.570 | 0.003 | 0.012 |
Proximal tumor site1 | 5 (26) | 1 (8) | 29 (49) | Â | Â | Â |
Distal tumor site2 | 14 (74) | 12 (92) | 29 (49) | 0.152 | < 0.001 | 0.001 |
ACPS Stage A or B | 8 (42) | 4 (31) | 36 (61) | Â | Â | Â |
ACPS Stage C or D | 11 (58) | 9 (69) | 23 (39) | 0.520 | 0.025 | 0.105 |
LVI Negative | 15 (79) | 6 (46) | 39 (66) | Â | Â | Â |
LVI Positive | 4 (21) | 7 (54) | 20 (34) | 0.049 | 0.188 | 0.126 |
EMVI Negative | 19 (100) | 8 (62) | 52 (88) | Â | Â | Â |
EMVI Positive | 0 (0) | 5 (38) | 7 (12) | 0.005 | 0.031 | 0.024 |
PNI Negative | 17 (89) | 11 (85) | 52 (88) | Â | Â | Â |
PNI Positive | 2 (11) | 2 (15) | 7 (12) | 0.744 | 0.506 | 0.708 |
TILS Negative3 | 9 (47) | 5 (38) | 26 (44) | Â | Â | Â |
TILS Positive | 7 (37) | 8 (62) | 33 (56) | 0.326 | 0.547 | 0.521 |
CIMPW - negative4 | 19 (100) | 10 (77) | 28 (47) | Â | Â | Â |
CIMPW - low | 0 (0) | 3 (23) | 15 (25) | Â | Â | Â |
CIMPW - high | 0 (0) | 0 (0) | 16 (27) | 1.000 | < 0.001 | < 0.001 |
MSI+ | 2 (11) | 0 (0) | 13 (18) | Â | Â | Â |
MSI- | 17 (89) | 13 (100) | 46 (78) | 0.125 | < 0.001 | 0.221 |
BRAF mutant | 0 (0) | 0 (0) | 15 (25) | Â | Â | Â |
BRAF wildtype | 19 (100) | 13 (100) | 44 (75) | 1.000 | < 0.001 | < 0.001 |
KRAS mutant | 3 (16) | 0 (0) | 26 (44) | Â | Â | Â |
KRAS wildtype | 16 (84) | 13 (100) | 33 (56) | 0.057 | < 0.001 | 0.014 |